文献速递骨质疏松与代谢性骨病创伤骨科

阿巴洛肽与安慰剂治疗后绝经后骨质疏松症女性前臂骨密度与骨折发生率:ACTIVExtend 3 期试验结果

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial.
PubMed 文献 · Osteoporos Int · 2020-09-15

ACTIVExtend 3 期试验后续分析纳入绝经后骨质疏松症女性,比较阿巴洛肽后接阿仑膦酸钠与安慰剂后接阿仑膦酸钠对前臂骨密度及腕部骨折的影响;超远端桡骨骨密度在 ABL/ALN 组增加而 PBO/ALN 组下降,腕部骨折风险两组无显著差异。

要点

  • 累计第 25 个月时超远端桡骨骨密度较 ACTIVE 基线平均增加 1.1%(ABL/ALN 组)vs 下降 0.8%(PBO/ALN 组),P<0.01
  • ABL 后的骨密度增益在 ACTIVExtend 中经 ALN 治疗维持至第 43 个月
  • 43 个月内腕部骨折 ABL/ALN 组 15 例(KM 估计 2.8%)vs PBO/ALN 组 20 例(KM 估计 3.6%),HR=0.77(95%CI 0.39, 1.50;P=无统计学显著性)

核心结论

  • ACTIVE 中 ABL 治疗后的超远端桡骨骨密度增益在 ACTIVExtend 的 24 个月 ALN 治疗期间得以维持。
  • 1/3 桡骨骨密度在 ACTIVE 期间下降后在 ACTIVExtend 的 ALN 治疗期间保持稳定。

研究设计与样本

  • ACTIVExtend 3 期试验的事先指定亚组分析。
  • 超远端和 1/3 桡骨骨密度测量:ABL/ALN 组 n=213,PBO/ALN 组 n=233。
  • 腕部骨折率在 ACTIVExtend 意向治疗人群(ABL/ALN 组 n=558,PBO/ALN 组 n=581)中用 Kaplan-Meier 法估计。

主要发现

  • 累计第 25 个月,超远端桡骨骨密度较 ACTIVE 基线平均增加:ABL/ALN 组 1.1%(标准误 0.49%)vs PBO/ALN 组 -0.8%(标准误 0.43%),P<0.01。
  • ABL 后的骨密度增加在 ACTIVExtend 中经 ALN 治疗维持至第 43 个月。
  • 1/3 桡骨骨密度在 ACTIVE 中下降(ABL 与 PBO 相似),在 ACTIVExtend 中经 ALN 治疗维持至 24 个月。
  • 43 个月内腕部骨折:ABL/ALN 组 15 例女性(KM 估计 2.8%)vs PBO/ALN 组 20 例(KM 估计 3.6%),HR=0.77(95%CI 0.39, 1.50;P=无统计学显著性)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial. Over the subsequent 24 months in ACTIVExtend, ultradistal radius BMD gains were maintained with alendronate. Conversely, 1/3 radius BMD remained stable during ALN treatment in ACTIVExtend after decreasing during ACTIVE. INTRODUCTION: Abaloparatide (ABL) increased femoral neck, total hip, and lumbar spine bone mineral density (BMD) in postmenopausal women with osteoporosis and decreased the risk of vertebral and nonvertebral fractures in ACTIVE. Effects on fracture risk and BMD were maintained subsequently with alendronate (ALN) in ACTIVExtend. In a prespecified subanalysis of ACTIVE, ABL also increased BMD at the ultradistal radius. Our objective was to determine the efficacy of ABL followed by ALN vs placebo (PBO) followed by ALN on forearm BMD and fracture risk over 43 months in ACTIVExtend. METHODS: Ultradistal and 1/3 radius BMD (ACTIVE baseline to month 43) were measured (ABL/ALN, n = 213; PBO/ALN, n = 233). Wrist fracture rates were estimated for the ACTIVExtend intent-to-treat population (ABL/ALN, n = 558; PBO/ALN, n = 581) by Kaplan-Meier (KM) method. RESULTS: At cumulative month 25, mean increase from ACTIVE baseline in ultradistal radius BMD was 1.1% (standard error, 0.49%) with ABL/ALN vs - 0.8% (0.43%) with PBO/ALN (P < 0.01). BMD increases with ABL were maintained with ALN through month 43 in ACTIVExtend. BMD decreases at the 1/3 radius in ACTIVE (similar with ABL and PBO) were maintained through 24 months of ALN treatment in ACTIVExtend. Wrist fractures over 43 months occurred in 15 women with ABL/ALN (KM estimate, 2.8%) and 20 with PBO/ALN (KM estimate, 3.6%) (HR = 0.77, 95% CI 0.39, 1.50; P = not significant). CONCLUSION: Ultradistal radius BMD gains following treatment with ABL in ACTIVE were maintained over 24 months of ALN treatment in ACTIVExtend. Conversely, 1/3 radius BMD remained stable during ALN treatment in ACTIVExtend after decreasing during ACTIVE. TRIAL REGISTRATION: ClinicalTrials.gov : NCT01657162 submitted July 31, 2012.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Watts NB, Dore RK, Baim S, et al. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial. Osteoporos Int. 2020. PMID: 32935170. doi:10.1007/s00198-020-05555-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。